BrightGene Financial Statements From 2010 to 2025

688166 Stock   29.38  0.17  0.58%   
BrightGene Bio financial statements provide useful quarterly and yearly information to potential BrightGene Bio Medical investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on BrightGene Bio financial statements helps investors assess BrightGene Bio's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting BrightGene Bio's valuation are summarized below:
Gross Profit
670.1 M
Profit Margin
0.1515
Market Capitalization
12.4 B
Enterprise Value Revenue
11.3295
Revenue
1.2 B
We have found seventy-five available fundamental signals for BrightGene Bio Medical, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of BrightGene Bio Medical prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

BrightGene Bio Total Revenue

751.16 Million

316.8M407.5M503.2M785.4M1.1B1.0B1.2B1.4B751.2M100%
Check BrightGene Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BrightGene Bio's main balance sheet or income statement drivers, such as Tax Provision of 14.9 M, Interest Income of 21.7 M or Interest Expense of 53.6 M, as well as many indicators such as . BrightGene financial statements analysis is a perfect complement when working with BrightGene Bio Valuation or Volatility modules.
  
This module can also supplement various BrightGene Bio Technical models . Check out the analysis of BrightGene Bio Correlation against competitors.

BrightGene Bio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets6.1 B5.8 BB
Slightly volatile
Other Current Liabilities26.6 M18.1 M33.7 M
Slightly volatile
Total Current Liabilities1.1 B1.1 B389 M
Slightly volatile
Total Stockholder Equity1.4 B2.7 B993.8 M
Slightly volatile
Net Tangible Assets1.2 B2.4 B919.4 M
Slightly volatile
Accounts Payable275.5 M262.4 M107.6 M
Slightly volatile
Cash1.2 B1.1 B398.5 M
Slightly volatile
Non Current Assets Total3.9 B3.7 B1.2 B
Slightly volatile
Non Currrent Assets Other184.6 M268.3 M113 M
Slightly volatile
Other Assets424.7 M404.5 M144 M
Slightly volatile
Net Receivables224.4 M325.4 M166.1 M
Slightly volatile
Short Term Investments45.2 M45.6 M57.6 M
Slightly volatile
Inventory416.1 M396.3 M163.2 M
Slightly volatile
Other Current Assets49.4 M75 M38.6 M
Slightly volatile
Total Liabilities3.2 BB891.3 M
Slightly volatile
Deferred Long Term Liabilities26.2 M30.9 M22.9 M
Slightly volatile
Short and Long Term Debt331.1 M656.5 M208.1 M
Slightly volatile
Total Current Assets1.1 B2.1 B768.8 M
Slightly volatile
Intangible Assets113.1 M107.7 M37.6 M
Slightly volatile
Common Stock280.6 M485.8 M201 M
Slightly volatile
Property Plant Equipment2.5 B2.4 B776.8 M
Slightly volatile
Other Liabilities21.5 M29.9 M13 M
Slightly volatile
Common Stock Shares Outstanding340.7 M485.8 M206.7 M
Slightly volatile
Net Invested Capital5.5 B5.2 B1.8 B
Slightly volatile
Net Working Capital745.5 M1.1 B505.7 M
Slightly volatile
Capital Stock389.3 M485.8 M211.6 M
Slightly volatile
Property Plant And Equipment Net1.5 B2.9 B822.8 M
Slightly volatile
Property Plant And Equipment Gross1.6 B3.1 B943.1 M
Slightly volatile
Long Term Debt1.1 B1.9 B474.3 M
Slightly volatile
Net Debt949.1 M1.4 B695.1 M
Slightly volatile
Good WillM6.8 M7.4 M
Slightly volatile
Capital Lease Obligations25.4 M24.2 MM
Slightly volatile

BrightGene Bio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision14.9 M17.6 M9.7 M
Slightly volatile
Interest Income21.7 M20.7 M4.7 M
Slightly volatile
Selling General Administrative74.7 M140.1 M63.1 M
Slightly volatile
Total Revenue751.2 M1.4 B548.5 M
Slightly volatile
Gross Profit438 M756.8 M317.2 M
Slightly volatile
Other Operating Expenses3.6 MMM
Slightly volatile
Operating Income177.2 M291.6 M116.8 M
Slightly volatile
Net Income From Continuing Ops142.9 M199.4 M92.7 M
Slightly volatile
EBIT147.1 M266.1 M111.9 M
Slightly volatile
Research Development154.7 M285.9 M117.9 M
Slightly volatile
Cost Of Revenue313.2 M599.6 M231.3 M
Slightly volatile
Total Operating Expenses574 M1.1 B431.7 M
Slightly volatile
Income Before Tax157.7 M217.1 M102.4 M
Slightly volatile
Net Income Applicable To Common Shares141.5 M275.6 M103.7 M
Slightly volatile
Net Income151.7 M232.8 M99.4 M
Slightly volatile
Income Tax Expense37.2 M35.4 M13.1 M
Slightly volatile
EBITDA213 M363.8 M158.8 M
Slightly volatile
Reconciled Depreciation94.3 M89.8 M34.5 M
Slightly volatile
Minority Interest35.1 M33.4 M8.8 M
Slightly volatile

BrightGene Bio Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation94.3 M89.8 M33.8 M
Slightly volatile
Dividends Paid137.4 M130.8 M41.8 M
Slightly volatile
Capital Expenditures371.7 M447.7 M233.9 M
Slightly volatile
Total Cash From Operating Activities141.4 M224 M98.3 M
Slightly volatile
Net Income151.4 M230.7 M99.1 M
Slightly volatile
End Period Cash Flow1.1 B1.1 B383.6 M
Slightly volatile
Begin Period Cash Flow764.8 M728.4 M249.9 M
Slightly volatile
Total Cash From Financing Activities1.6 B1.6 B525.3 M
Slightly volatile

About BrightGene Bio Financial Statements

BrightGene Bio stakeholders use historical fundamental indicators, such as BrightGene Bio's revenue or net income, to determine how well the company is positioned to perform in the future. Although BrightGene Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in BrightGene Bio's assets and liabilities are reflected in the revenues and expenses on BrightGene Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BrightGene Bio Medical. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue1.4 B751.2 M
Cost Of Revenue599.6 M313.2 M

Currently Active Assets on Macroaxis

Other Information on Investing in BrightGene Stock

BrightGene Bio financial ratios help investors to determine whether BrightGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BrightGene with respect to the benefits of owning BrightGene Bio security.
News Freq…Investor S…